
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Analysts at B. Riley upped their Q2 2025 earnings per share (EPS) estimates for shares of Eton Pharmaceuticals in a research report issued to clients and investors on Wednesday, July 16th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of ($0.01) for the quarter, up from their previous forecast of ($0.04). B. Riley currently has a "Buy" rating and a $26.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' FY2025 earnings at $0.52 EPS, FY2028 earnings at $2.25 EPS and FY2029 earnings at $2.51 EPS.
Several other research analysts also recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Craig Hallum lifted their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th.
Read Our Latest Research Report on Eton Pharmaceuticals
Eton Pharmaceuticals Trading Up 0.5%
ETON traded up $0.08 during midday trading on Monday, hitting $15.37. 448,049 shares of the company were exchanged, compared to its average volume of 654,254. The firm has a market capitalization of $412.22 million, a P/E ratio of -85.39 and a beta of 1.18. Eton Pharmaceuticals has a 1-year low of $3.25 and a 1-year high of $21.48. The firm's 50 day moving average price is $15.99 and its 200-day moving average price is $15.34. The company has a quick ratio of 1.43, a current ratio of 1.97 and a debt-to-equity ratio of 1.23.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.02). The firm had revenue of $17.28 million for the quarter, compared to analyst estimates of $14.33 million. Eton Pharmaceuticals had a negative net margin of 9.49% and a negative return on equity of 3.15%.
Insider Buying and Selling
In related news, insider David Krempa sold 10,223 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $14.73, for a total value of $150,584.79. Following the completion of the sale, the insider directly owned 612,646 shares of the company's stock, valued at $9,024,275.58. The trade was a 1.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders sold 34,000 shares of company stock valued at $504,318. Insiders own 16.03% of the company's stock.
Institutional Trading of Eton Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AlphaQuest LLC acquired a new position in Eton Pharmaceuticals during the 1st quarter valued at about $53,000. Tower Research Capital LLC TRC acquired a new position in Eton Pharmaceuticals during the 4th quarter valued at about $86,000. Quantbot Technologies LP purchased a new position in shares of Eton Pharmaceuticals in the 1st quarter worth approximately $101,000. Jefferies Financial Group Inc. purchased a new position in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $133,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Eton Pharmaceuticals by 18.3% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock worth $141,000 after buying an additional 1,634 shares during the last quarter. 27.86% of the stock is owned by institutional investors.
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Featured Stories

Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.